December 2019. Volume 15. Number 4

Antimenigococcal vaccine B FHbp. Would a booster dose be advisable?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Vesikari T, Østergaard L, Beeslaar J, Absalon J, Eiden JJ, Jansen KU, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents. Vaccine. 2019;37:1710-9.

Reviewers: Rivero Martín MJ1, García Vera C2.
1Departamento de Medicina. Universidad Rey Juan Carlos. Servicio de Pediatría. Hospital Universitario de Fuenlabrada. Fuenlabrada. Madrid. España.
2Pediatra. CS José Ramón Muñoz Fernández. Zaragoza. España.
Correspondence: M.ª José Rivero Martín. Email: mriverom@salud.madrid.org
Reception date: 27/08/2019
Acceptance date: 10/09/2019
Publication date: 16/10/2019

Abstract

Authors’ conclusions: the immune response to the booster dose was similar regardless of whether the primary vaccination schedule consisted of 2 or 3 doses. A Meningococcus B (Trumemba®) booster dose 4 years after receiving the primary vaccination, appears safe, well tolerated and leads to a strong immune response that indicates immunological memory.

Reviewers’ commentary: after a booster dose 4 years after the primary vaccination with a bivalent vaccine against Meningococcus B (Trumemba®), it is possible to reactivate the immune response in adolescents against the tested strains of this bacterium, regardless of whether the primary vaccination was done with 2 or 3 doses. The immune response has only been assessed a month after reinforcement.

How to cite this article

Rivero Martín MJ, García Vera C. Vacuna antimeningocócica B FHbp. ¿Sería conveniente una dosis de refuerzo? Evid Pediatr. 2019;15:36.

AVC | Critically appraised articles

Vesikari T, Østergaard L, Beeslaar J, Absalon J, Eiden JJ, Jansen KU, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents. Vaccine. 2019;37:1710-9.

Reviewers: Rivero Martín MJ1, García Vera C2.
1Departamento de Medicina. Universidad Rey Juan Carlos. Servicio de Pediatría. Hospital Universitario de Fuenlabrada. Fuenlabrada. Madrid. España.
2Pediatra. CS José Ramón Muñoz Fernández. Zaragoza. España.
Correspondence: M.ª José Rivero Martín. Email: mriverom@salud.madrid.org
Reception date: 27/08/2019
Acceptance date: 10/09/2019
Publication date: 16/10/2019

How to cite this article

Rivero Martín MJ, García Vera C. Vacuna antimeningocócica B FHbp. ¿Sería conveniente una dosis de refuerzo? Evid Pediatr. 2019;15:36.


Related Articles

ED | Cerrando el círculo en torno a las meningitis meningocócicas: ¿lo conseguiremos?

Ortigosa del Castillo L. Cerrando el círculo en torno a las meningitis meningocócicas: ¿lo conseguiremos?. Evid Pediatr. 2019;15:43.
16/10/2019

Linked Comment